Navigation Links
Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments

y the FDA to treat the disease.

Some migraine patients mistakenly think their medication is not addictive: 36 percent of patients taking barbiturates or opioids as their primary migraine prescription medication said the phrase "not addictive" describes their medication "extremely" or "very" well, according to the survey.

Few physicians surveyed prescribe barbiturates or opioids (2% and 1% respectively) as a first-line acute treatment for migraines, but general practitioners are more likely than neurologists to prescribe opioids as a second-line treatment, the survey found. Twenty-five percent of general practitioners say they would prescribe opioids as a second-line therapy for migraines, compared with just 7 percent of neurologists.

"Though it's encouraging that the survey showed 53 percent of migraine patients are now on triptans, an approved drug class, the fact that 20 percent of patients continue to take medications unapproved to treat migraine indicates that additional physician education could be helpful" said Suzanne Simons, executive director of the National Headache Foundation.

Simple Steps to Achieving Optimal Migraine Treatment

While there is no cure for migraines, taking the right medication below to effectively treat your migraine will minimize how they affect your daily life. Here are a few steps you can take to help optimize your migraine treatment.

    -- Observe. Make note of any side effects that you experience from your

       migraine medication which may affect your daily activities.

    -- Communicate. Keep a headache journal or diary. The journal may include

       when the headache occurred, its severity, duration, location and

       whether the medication you took to treat it was effective. You can

       download a free headache diary at http://www.headaches.org

    -- Use self-management techniques -- There are ways to manage your

'"/>




Page: 1 2 3 4 5 6 

Related medicine technology :

1. Frova Phase III Study Data Demonstrates That Short-Term Prevention
Treatment Reduces Frequency and Severity of Menstrual Migraine
2. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free
Response Across Multiple Attacks
3. NuPathe Reports Positive Phase One Results for NP101 Transdermal
Therapy for Acute Migraine
4. Mercks Investigational Migraine Treatment MK-0974 Significantly
Improved Migraine Pain on Several Efficacy Measures in a Phase II
Study
5. Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both
Traditional and Non-traditional Migraine Symptoms
6. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across
Multiple Migraine Attacks
7. Addex Reports Positive Results in Phase IIa Clinical Trial With
ADX10059 in Migraine
8. Hematology Analyzers   Simple, Sophisticated Technology Serving All Patients
9. Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis
10. International ENDORSE Study Shows That the Majority of Hospitalized
Patients Surveyed are at Risk for VTE and Many do not Receive
Recommended VTE prophylaxis
11. Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:12/15/2009)... Wis., Dec. 16 Cellular ... commercial launch of iCell(TM) Cardiomyocytes for use in ... industry. These human heart cells are designed ... of drug compound efficacy and toxicity screens, weeding ... the pharmaceutical pipeline process before significant time and ...
(Date:12/15/2009)... INCLINE VILLAGE, Nev., Dec. 15 PDL BioPharma, ... it has paid the December 15, 2009 special dividend ... shares of PDL as of December 1, 2009. ... ended December 31, 2009 total $2.67 per share. ... regarding the federal tax characteristics of the Company,s 2009 ...
(Date:12/15/2009)... 15 The U.S. Food and Drug Administration ... voted 12 yes, 4 no, and 1 abstention that ... risks to support the use of CRESTOR® (rosuvastatin calcium) ... greater than or equal to 50 years, women greater ... LDL < 130 mg/dL; hsCRP greater than or equal ...
Breaking Medicine Technology:Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 2Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 3Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 4PDL BioPharma Completes December 15 Special Dividend Payment 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5Energy X Lip Balm Delivers Wake Up Call to Consumers 55004 1Energy X Lip Balm Delivers Wake Up Call to Consumers 55004 2The Sensory Research Center 28SRC 29 Offers 2 for 1 Tickets for Benefit Concert Supporting Autism Downs Syndrome Cerebral Palsy and Other Disabilit 55001 1The Sensory Research Center 28SRC 29 Offers 2 for 1 Tickets for Benefit Concert Supporting Autism Downs Syndrome Cerebral Palsy and Other Disabilit 55001 2Study finds low risk in treating previously coiled aneurysm 54998 1Study finds low risk in treating previously coiled aneurysm 54998 2Study finds low risk in treating previously coiled aneurysm 54998 3
(Date:12/15/2009)... a Life Sciences company engaged in the research, development and commercialization of technologies that target ... the Company had proposed at the Annual General Meeting of Shareholders held on December 14, ... Votes ... Non-, Matter ... For Against ...
(Date:12/15/2009)... Lourdes Health Care Services Inc., the parent company of ... United States $7.95 million to resolve allegations that the ... two hospitals are Our Lady of Lourdes Medical Center ... Burlington County (LMC) in Willingboro, N.J. ,, LMC ... whistleblower, Tony Kite, in 2005. The lawsuit alleged that ...
(Date:12/15/2009)... doses have lower strength than needed for protection, CDC ... 800,000 children,s doses of H1N1 swine flu vaccine have ... have lost some potency, federal health officials said Tuesday. ... and Prevention, the company,s routine testing of the vaccine ... found that four batches had lower than required potency ...
(Date:12/15/2009)... 4R Systems, Inc., a leading provider ... help retailers significantly increase profits by optimizing their ... that The Vitamin Shoppe has been utilizing the ... and DC inventory solutions have helped us drive ... over the last two years," said Tony Truesdale, ...
(Date:12/15/2009)... -- North American application activity for individually underwritten ... to the MIB Life Index(SM) . ... past three months have lifted year-to-date (YTD) figures ... flat at November,s close, -0.1%. "It is ... benefits available from life insurance," says Stacy Gill, ...
Breaking Medicine News(10 mins):Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3
... Swartz Center for Computational Neuroscience at UC San Diego ... body/brain dynamics of subjects engaged in normal activity in ... under a four year, $3.4 million research grant from ... developing a concurrent brain and body imaging modality MoBI ...
... Healthcare Management Systems,Inc.(R) (HMS) hospital customers completed three ... painted were entered into a drawing,to receive the paintings ... another,hospital. Recipients of the 4-foot by 6-foot, multiple-canvas paintings ... of HMS, annual,conference. , , ...
... Md., Dec. 10 Approximately 38 percent of adults in ... 12 percent of U.S. children aged 17 years and under ... to a new nationwide government survey (1). ... on children,s use of CAM, which is a group of ...
... Epiretinal Brachytherapy Granted Compassionate Use to Attempt to Prevent ... , FREMONT, Calif., Dec. 10 ... Drug Administration (FDA) had approved the company,s "compassionate case" ... (AMD) treatment on a patient with an advanced form ...
... neurodegenerative diseases , , WEDNESDAY, Dec. 10 (HealthDay News) -- ... death of neurons in the brains of patients with ... U.S. researchers. , The finding could help in the ... , The scientists focused on an enzyme called HDAC1, ...
... As do 12% of children, new government survey says ... estimated 38 percent of U.S. adults and 12 percent ... medicine, a new U.S. government survey finds. , Complementary ... an umbrella term for a collection of wide-ranging medical ...
Other Medicine News:Health News:HMS Donates Hospital Art 2Health News:According to a New Government Survey, 38 Percent of Adults and 12 Percent of Children Use Complementary and Alternative Medicine 2Health News:According to a New Government Survey, 38 Percent of Adults and 12 Percent of Children Use Complementary and Alternative Medicine 3Health News:According to a New Government Survey, 38 Percent of Adults and 12 Percent of Children Use Complementary and Alternative Medicine 4Health News:According to a New Government Survey, 38 Percent of Adults and 12 Percent of Children Use Complementary and Alternative Medicine 5Health News:FDA Grants NeoVista's Request to Utilize Novel Wet AMD Treatment in Compassionate Case 2Health News:FDA Grants NeoVista's Request to Utilize Novel Wet AMD Treatment in Compassionate Case 3Health News:38% of U.S. Adults Use Alternative Treatments 2Health News:38% of U.S. Adults Use Alternative Treatments 3
... of three software components that comprise ... ,Three software components comprise the SmartPill ... software, SmartPill Data Receiver software and ... are integrated and indispensable parts of ...
... software links sampler, patient and ... making data readily available to ... of incorrect patient identification. ... 1st automatic, the worlds first ...
... One of three software components that ... ,Three software components comprise the ... Capsule software, SmartPill Data Receiver software ... components are integrated and indispensable parts ...
... Testing Application for POLYGRAM NET® ... Catheter-Free pH Monitoring System, Digitrapper™ ... Synectics Digitrapper MkIII catheter-based pH ... and Digitrappers use Medtronic Slimline®, ...
Medicine Products: